Document:

<PAGE>

                                                                  Exhibit 10.17*

The confidential portions of this exhibit, which have been removed and
replaced with an asterisk, have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment under Rule 406.

                          AMENDMENT TO SUPPLY AGREEMENT

      This AMENDMENT TO SUPPLY AGREEMENT (the "Amendment") is made and entered
into this _________day of _____________, 1996, (the "Effective Date"), between
WILSON GREATBATCH LTD., ("WGL") an New York corporation, and MEDTRONIC, INC.,
("Medtronic") a Minnesota corporation.

                                   WITNESSETH

      WHEREAS, Medtronic and WGL have entered into a Supply Agreement dated July
31, 1991, whereby WGL will manufacture and supply SVO batteries to Medtronic for
use in medical devices sold by Medtronic.

      WHEREAS, Medtronic and WGL desire to amend certain terms of the Supply
Agreement in writing as required in Section 13.6 of the Supply Agreement.

      NOW, THEREFORE, in consideration of the premises and of the mutual
covenants and agreements contained herein, and for good and valuable
consideration, the receipt and adequacy whereof is mutually acknowledged, the
parties hereby amend the terms end provisions of the Supply Agreement, and
otherwise agree as follows:

      1. Development. The capitalized tern's used and not otherwise defined
herein shall have the meanings ascribed thereto in the Supply Agreement

      2. Development. Subject to the terms of this Amendment, WGL has agreed to
develop the cell whose specifications are set forth on Exhibit A hereto
(hereinafter the "7221 cell") at no development cost to Medtronic. The parties
agree that for the 7221 Cell the terms of Article 6.3 of the Supply Agreement
shell not be applicable. WGL agrees to provide qualified cells and data for
submission to the FDA to Medtronic no later than December 1, 1996.

      3. 7221 Cell Price. The parties agree that the price for the 7221 Cell
shall be * per unit. The parties agree that Article 6.10, Permitted Price
Adjustments, shall not apply to the increase of the 7221 Cell price from * to *.
However, subsequent increases in the price of the 7221 Cell shall be subject to
Article 6.10. The parties further agree that the price for the 7221 Cell shall
not trigger an audit by Medtronic under Article 6.10(b) or trigger the quota
reductions set forth in Article 6.10(c).
<PAGE>

      4. Purchase Commitment. Subject to the terms of Section 3 end 4 above and
section 5 below, Medtronic agrees to purchase at least * of the 7221 cells.
Provided, Medtronic's commitment to purchase shall be subject to following
adjustments:

      a)    In the event WGL fails to provide qualified cells and adequate
            battery data for submission to the FDA by December 1, 1996, the
            purchase requirement shall be reduced by * cells for every day such
            qualified cells and data are not available.

      b)    In the event WGL cannot provide * units by December 15, 1996 and the
            remainder of the * units on a mutually agreeable delivery schedule,
            Medtronic's commitment to purchase 7221 cells shall be reduced by *
            cells for every failure of WGL to meet a scheduled delivery date.

      5. FDA Delay/Lack of Approval. In the event there is a delay in the FDA
approval of the device for which these cells are intended or the device is not
approved by the FDA for any reason, WGL and Medtronic agree to negotiate in good
faith to eliminate, reduce or replace the purchase requirement under Section 4,
above, and compensate WGL far reasonable development expenses.

      6. Advance Payment/Inventory Requirement. The parties agree that Article
6.7 of the Supply Agreement shall be amended as follows;

      a)    Subject to Section 6(b) below, the inventory requirement under
            Article 6.7 of the Supply Agreement shall be reduced to * units upon
            execution of this Amendment and will be further reduced to * units
            upon receipt of the October 31, 1996 payment as set forth below.

      b)    In consideration for the inventory reductions set forth is Section
            6(b) above, WGL shall repay * of the advance payment made pursuant
            to Article 6.7 of the Supply Agreement as amended. Such payment to
            be made in equal installments on or before October 31, 1996 and
            December 31, 1996. Failure to make such payments will reinstate the
            inventory requirements of Article 6.7 of the Supply Agreement.

                                       2
<PAGE>

      7. Other Terms Remain in Effect/Conflict. Except as modified in this
Amendment all terms and provisions of the Supply Agreement, shall remain in
force and effect. In the event of a conflict between the terms of this amendment
and the Supply Agreement, the Supply Agreement shall control.

      IN WITNESS WHEREOF, each of the parties has caused this Amendment to the
Development Agreement to be executed in the manner appropriate to each.

WILSON GREATBATCH LTD.

By: /s/ Edward F. Voboril
   --------------------------------
   Edward F. Voboril. President

Dated: 5-23-96
      -----------------------------

MEDTRONIC, INC.

By: /s/ B Kristine Johnson
   --------------------------------
   B Kristine Johnson
   President
   Tachyarrythtmia Management Business

Dated: 6-3-96
      -----------------------------

                                       3<PAGE>

                                                                  Exhibit 10.18*

The confidential portions of this exhibit, which have been removed and
replaced with an asterisk, have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment under Rule 406.

                                SECOND AMENDMENT
                               TO SUPPLY AGREEMENT

This SECOND AMENDMENT is made to the Supply Agreement between WILSON GREATBATCH
LTD. ("WGL") and MEDTRONIC, INC. ("Medtronic") dated July 31, 1991 (the "Supply
Agreement") and to the first Amendment to that Supply Agreement dated June 3,
1996 (the "First Amendment").

                                    RECITALS

Medtronic and WGL desire to amend certain terms of the Supply Agreement and
First Amendment to Supply Agreement in writing pursuant to Section 13.6 of the
Supply Agreement.

The parties therefore agree as follows:

1.    Supply. The parties agree that WGL will become the exclusive supplier of
      SVO batteries for Medtronic Model 7221 and Model 7271 implantable cardiac
      defibrillators, contingent upon WGL's ability to meet existing or mutually
      agreed to modifications of existing battery specifications and qualify the
      batteries and subject to Medtronic's ability to receive FDA approval for
      the use of the WGL batteries within the Medtronic products identified.
      Medtronic will use its best commercial efforts to secure approval for use
      of the WGL product on a timely basis.

2.    Failure to Meet Delivery Schedules. The parties agree that if WGL is
      unable for any reason other than force majeure to meet any scheduled
      deliveries specified by Medtronic for the SVO batteries identified under
      Section 1 hereof, Medtronic shall be flee to make or have made SVO
      batteries which meet Medtronic's product needs.

3.    Unit Price. The parties agree that the price for the 7221 and 7271 SVO
      battery shall be * each. Any subsequent price increases in the price of
      the 7221 and/or 7271 shall be subject to Section 6.10.

4.    Design Fee Medtronic agrees to pay WGL a design fee of * for the
      development of the WGL battery to be used in Medtronic's Model 7271
      device. Medtronic shall pay the design fee to WGL as follows:

      * Upon Receipt of purchase order

      * Upon WGL's completion of engineering prototypes; and

      * Upon completion of the qualification of the cell by WGL and Medtronic
<PAGE>

5.    Advance Payment. The parties the First Amendment to the Supply Agreement,
      WGL repaid * of the advance payment made pursuant to Section 6.7 of the
      Supply Agreement. The parties further agree that WGL shall hold the
      balance of the advance payment in the amount of *. Said amount will be
      considered an advance and will be applied to the final purchases under the
      final Contract Period. The parties further agree that WGL shall not be
      required to maintain any finished goods as security for the remaining *
      advance payment; however, WGL will use its best commercial efforts to
      satisfy Medtronic's supply needs under this Second Amendment. WGL shall
      have no continuing obligation to provide any security for its obligation
      to repay the remaining * of the advance payment referred to in Article 6.7
      of the Supply Agreement, as amended, and the Security Agreement is hereby
      terminated.

6.    Quota. WGL and Medtronic agree that WGL will waive the minimum purchase
      requirements for the remainder of the Second Contract Period. Medtronic
      agrees to report on its usage of SVO batteries pursuant to the terms of
      the Supply Agreement. This amendment shall not effect, or operate as a
      waiver by WGL of, Medtronic's obligations under Section 5.2(c) with
      respect to the Third Contract Period or the quota of SVO Batteries to be
      purchased by Medtronic in each Contract Year of the Third Contract Period
      which are set forth in Section 5.1. The parties further agree that the
      price for the 7221 Cell and 7271 Cell shall not trigger a quota reduction
      for the Third Contract Period pursuant to Section 6.10(c).

7.    Other Terms Remain in Effect. Except as modified by this Second Amendment,
      all terms and provisions of the Supply Agreement and First Amendment shall
      remain in full force and effect.

With their signature below, each of the parties indicates they have read,
understand and agreed to the terms of this Second Amendment.

MEDTRONIC, INC.

By /s/ Jon T. Tremmel                   Date: 3/14/97
  ---------------------------------
  Jon T. Tremmel, Vice President and
  President Tachyarrhythmia Management
  Business

WILSON BREATBATCH LTD.

By /s/ Edward F. Voboril                Date: 3/24/97
  ---------------------------------          -----------------------------------
  Edward F. Voboril, President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]